Stifel Downgrades Threshold Pharmaceuticals (THLD) to Hold
Get Alerts THLD Hot Sheet
Rating Summary:
7 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Join SI Premium – FREE
Stifel downgraded Threshold Pharmaceuticals (NASDAQ: THLD) from Buy to Hold after the company announced negative topline data from both of its Phase III trials for TH-302 in pancreatic cancer and sarcoma.
Analyst Thomas Shrader commented, "Despite very positive phase II data, the pancreatic cancer again narrowly missed the OS endpoint (HR=0.84). The sarcoma trial showed no treatment effect. Based on the overwhelming preclinical data that TH-302 was reaching and penetrating tumors with an active chemotherapy we believe these results cast significant doubt on the fundamental focus of Threshold’s pipeline. The company currently has about $56.4 million in cash and this forms the basis of our valuation."
For an analyst ratings summary and ratings history on Threshold Pharmaceuticals click here. For more ratings news on Threshold Pharmaceuticals click here.
Shares of Threshold Pharmaceuticals closed at $3.34 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- META to capture largest share of users, SNAP to benefit from ad budget shifts - Canaccord Genuity weighs in on TikTok ban
- JPMorgan Downgrades Monster Beverage (MNST) to Neutral, 'Cost Pressures and Weaker Low-end Consumer'
- Teradyne (TER) PT Raised to $125 at TD Cowen
Create E-mail Alert Related Categories
Analyst Comments, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!